Fig. 17From: Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathwaySchematic illustration of the proposed mechanisms underlying EDA-related antidepressant and anxiolytic efficacyBack to article page